Effect of Topical Adapalene 0.1% and Benzoyl Peroxide 2.5% on Tear Film and Ocular Surface in Patients with Facial Acne Vulgaris

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20260421008

Enrollment

Registered

2026-04-21

Start date

2025-04-09

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Facial acne vulgaris acne vulgaris, adapalene, benzoyl peroxide, dry eye disease, meibomian gland dysfunction

Interventions

Prospective observational pre-post study Adult patients aged at least 18 years with facial acne vulgaris attending the Dermatology Clinic at King Chulalongkorn Memorial Hospital, who were prescribed a

Treatment

facial acne vulgaris treated with adapalene 0.1% and benzoyl peroxide 2.5%

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Adult patients aged at least 18 years with facial acne vulgaris attending the Dermatology Clinic at King Chulalongkorn Memorial Hospital who were prescribed a fixed-dose topical combination of adapalene 0.1% and benzoyl peroxide 2.5%

Exclusion criteria

Exclusion criteria: 1. Documented hypersensitivity to retinoids or benzoyl peroxide. 2. Pregnancy or planned pregnancy. 3. Systemic conditions associated with dry eye disease. 4. Ocular disorders including lagophthalmos or thyroid-related orbitopathy. 5. History of ocular surgery or eyelid surgery. 6. Any ocular surface inflammation or infection within the previous month prior to enrollment. 7. Receiving systemic macrolides, tetracyclines, or oral retinoids (or having discontinued oral retinoids within one month prior to enrollment). 8. Undergoing concurrent treatment for dry eye disease or meibomian gland dysfunction.

Design outcomes

Primary

Measure	Time frame
Non-invasive tear film break-up time (NIBUT) Baseline and a follow-up visit at 6 weeks after treatment initiation seconds	—

Secondary

Measure	Time frame
Ocular Surface Disease Index (OSDI) Baseline and a follow-up visit at 6 weeks after treatment initiation scores,Tear film lipid layer thickness (TFLLT) Baseline and a follow-up visit at 6 weeks after treatment initiation nanometers,Percentage of upper-eyelid meibomian gland area Baseline and a follow-up visit at 6 weeks after treatment initiation percent ,Corneal fluorescein staining Baseline and a follow-up visit at 6 weeks after treatment initiation NEI scores,Lid margin abnormalities Baseline and a follow-up visit at 6 weeks after treatment initiation score,Meibum quality and meibum expressibility Baseline and a follow-up visit at 6 weeks after treatment initiation score	—

Measure

Time frame

Ocular Surface Disease Index (OSDI) Baseline and a follow-up visit at 6 weeks after treatment initiation scores,Tear film lipid layer thickness (TFLLT) Baseline and a follow-up visit at 6 weeks after treatment initiation nanometers,Percentage of upper-eyelid meibomian gland area Baseline and a follow-up visit at 6 weeks after treatment initiation percent ,Corneal fluorescein staining Baseline and a follow-up visit at 6 weeks after treatment initiation NEI scores,Lid margin abnormalities Baseline and a follow-up visit at 6 weeks after treatment initiation score,Meibum quality and meibum expressibility Baseline and a follow-up visit at 6 weeks after treatment initiation score

—

Countries

Thailand

Contacts

Public ContactTheep Mahasuweerachai

Department of Ophthalmology, Faculty of Medicine, Chulalongkorn University

newtheeptheep@gmail.com0959489908

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026